Prescribing menopausal hormone therapy: an evidence-based approach

Area of Science:

• Reproductive Endocrinology
• Cardiovascular Health
• Geriatric Medicine

Background:

• Menopausal hormone therapy (MHT) use has faced evolving guidelines and patient concerns.
• Reanalysis of Women's Health Initiative data and recent studies offer updated insights into MHT risks and benefits.

Purpose of the Study:

• To clarify the risk-benefit profile of systemic MHT based on age and time since menopause.
• To guide clinical decisions for menopausal hormone therapy.

Main Methods:

• Review and reanalysis of existing data, including the Women's Health Initiative.
• Consideration of age, years since menopause, and route of administration.

Main Results:

• For women <60 or within 10 years of menopause, MHT benefits generally outweigh risks, potentially reducing cardiovascular disease and cognitive decline.
• Early MHT may slow atherosclerotic disease progression and offer cognitive protection.
• Non-oral estrogen administration avoids hepatic metabolism, improving the risk profile.
• Combined MHT use >5 years increases breast cancer risk; estrogen-only MHT has less clear limitations.

Conclusions:

• MHT is a low-risk, acceptable option for symptomatic women <60 or within 10 years of menopause, especially when nonhormonal therapies fail.
• MHT initiated early in menopause appears cardioprotective and may benefit cognition.
• Careful consideration of age, time since menopause, and duration of therapy is crucial for optimizing MHT's risk-benefit balance.